DataSheet1_The Therapeutic Potential of Galectin-3 in the Treatment of Intrahepatic Cholangiocarcinoma Patients and Those Compromised With COVID-19.PDF
The novel coronavirus pneumonia COVID-19 is characterized by all age susceptibility, which imposes a dramatic threat to the human species all over the world. According to current available data, the cytokine storm appears to be the most life-threatening symptom of severe COVID-19 cases accompanied with lung fibrosis. Galectin-3 (Gal-3), a member of soluble β-galactoside-binding lectin families, has been implicated as a key regulator in various inflammation conditions in addition to its well-documented roles in cancer. The pro-inflammatory activity of Gal-3 in the inflammatory response and lung fibrosis of COVID-19 has been proposed by emerging studies, which suggested that inhibition of Gal-3 may represent a novel treatment approach for COVID-19 patients. Intrahepatic cholangiocarcinoma (ICC) is an aggressive malignancy with poor prognosis. ICC accounts for 10–25% of primary liver cancers with limited therapeutic options, which has higher incidence in Asian countries, particularly in China. Cancer patients, including ICC patients, are highly vulnerable to COVID-19 due to their impaired immune system. It is thus undoubtedly a challenge for our oncology department to establish effective treatment strategies under the influence of the COVID-19 crisis. According to our management procedures in the COVID-19 era, emergency treatment will be applied to ICC patients who are under life-threatening conditions, despite the COVID-19 infection. To the best of our knowledge, the modulatory function of Gal-3 in ICC is still barely explored to date. In order to evaluate the therapeutic potential of Gal-3 for ICC patients or those comprised with COVID-19, we herein report our preliminary investigation into roles of Gal-3 in ICC. Our results exhibited that the expression of Gal-3 was significantly up-regulated in ICC tissues, and a significant correlation was observed between its overexpression and malignant progression of ICC cells. We further discussed the activity and possible molecular mechanisms of Gal-3 in ICC, which may pave the ways for further exploring the possibility of Gal-3 as a potential therapeutic target for treating ICC patients or those with COVID-19-related conditions.
History
References
- https://doi.org//10.1038/bjc.2017.388
- https://doi.org//10.1128/mcb.00064-16
- https://doi.org//10.1186/s12974-019-1595-0
- https://doi.org//10.1016/j.jhep.2014.01.021
- https://doi.org//10.1016/j.cmi.2020.04.023
- https://doi.org//10.1038/s41467-020-17292-4
- https://doi.org//10.1038/s41416-020-0971-y
- https://doi.org//10.3892/ijmm.2017.3311
- https://doi.org//10.1001/jamasurg.2016.1769
- https://doi.org//10.3389/fimmu.2020.01328
- https://doi.org//10.1016/S0140-6736(20)30183-5
- https://doi.org//10.1186/s12974-020-01784-7
- https://doi.org//10.1093/glycob/cwn104
- https://doi.org//10.1016/j.immuni.2017.08.008
- https://doi.org//10.1016/S0140-6736(03)13967-0
- https://doi.org//10.1523/JNEUROSCI.1498-12.2012
- https://doi.org//10.1016/j.ijbiomac.2019.09.118
- https://doi.org//10.1016/S1470-2045(20)30096-6
- https://doi.org//10.1038/s41591-020-0901-9
- https://doi.org//10.1111/j.1749-6632.2011.06386.x
- https://doi.org//10.1080/17474124.2017.1309290
- https://doi.org//10.1038/s41586-019-1631-3
- https://doi.org//10.1038/nrclinonc.2017.157
- https://doi.org//10.3389/fimmu.2020.524826
- https://doi.org//10.1016/j.jhep.2003.11.030
- https://doi.org//10.1093/cid/ciy595
- https://doi.org//10.1016/s0039-6060(99)70024-3
- https://doi.org//10.1016/j.cgh.2009.08.023
- https://doi.org//10.1016/j.cca.2014.01.019
- https://doi.org//10.1038/s41416-020-1022-4
- https://doi.org//10.1099/mic.0.000322
- https://doi.org//10.3233/THC-192011
- https://doi.org//10.1200/JCO.2012.41.5984
- https://doi.org//10.1016/j.cardfail.2016.11.006
- https://doi.org//10.1189/jlb.3A0116-026RR
- https://doi.org//10.1001/jama.2020.2648
- https://doi.org//10.1074/jbc.RA120.012974
- https://doi.org//10.3164/jcbn.20-27
- https://doi.org//10.1038/s41591-019-0695-9
- https://doi.org//10.1016/j.jacc.2018.11.042
CC BY 4.0